Ribociclib
KISQALI
NADAC/unit
$289.7167
No Shortage
Tier 1: 53.8%
PA Req: 298.2%
KISQALI FEMARA CO-PACK, a co-packaged product containing ribociclib, a kinase inhibitor, and letrozole, an aromatase inhibitor, is indicated: for the adjuvant treatment of adults with hormone recep....
vs. brand KISQALI: Generic saves up to -2797% per unit
Generic Manufacturers
NOVARTIS PHARMACEUTICALS CORP
Explore in the Ecosystem
Data sourced from CMS NADAC, FDA Orange Book, CMS Part D Formulary, CMS Part D Spending, openFDA, and HRSA 340B OPAIS. Prices reflect National Average Drug Acquisition Cost and may not represent actual transaction prices. This information is for research and comparison purposes only. Consult your pharmacist or benefits consultant for plan-specific pricing.